Reports
Sale
Global Pharmaceuticals Market Size, Analysis, Forecast: By Molecule Type: Biologics and Biosimilars (Large Molecules), Conventional Drugs (Small Molecules); By Product; By Availability: OTC, Prescription; By Therapeutic Area; By Route of Administration; By Formulation; By Age Group; Regional Analysis; Supplier Landscape; 2024-2032
Global Pharmaceuticals Market Size
The global pharmaceuticals market was valued at USD 1467.14 billion in 2023 driven by strategic merger and acquisition activities and rising investment in infrastructure expansion across the globe. The market is projected to grow at a CAGR of 6.20% between 2024 and 2032, reaching a value of around USD 2466.16 billion by 2032.
Global Pharmaceuticals Market Outlook
- The rising burden of chronic diseases and the growing geriatric population are directly impacting the market value.
- Growing demand for biologic therapies and increased strategic mergers and acquisitions in the pharmaceutical sector are major market trends.
- Supportive government initiatives and increasing investment in healthcare infrastructure are some of the factors bolstering the market expansion in the Asia Pacific region.
Global Pharmaceuticals Market Overview
Ongoing innovations in product development, growth of the geriatric population fuelling the demand for more effective pharma solutions, and rising demand for personalized medicines are some of the prominent market drivers. The demand for personalized medicine solutions is growing due to the surge in demand for targeted treatment and therapies.
Market players are establishing collaborations for the expansion of their pharmaceutical capabilities. Novartis Pharma AG announced in May 2024 that it is actively strengthening its radiopharmaceutical capabilities and has extended its partnership with Peptidream Inc. in an agreement valued at a staggering USD 2.71 billion.
Moreover, some pharma providers are expected to establish a prominent position in the pharmaceuticals market due to the breakthroughs in their research. For instance, Amgen announced that in May 2024 it has obtained FDA approval for its promising lung cancer drug, Imdelltra, which signifies a major milestone in its oncology product portfolio.
Other factors influencing the market dynamics include increased government initiatives and supportive healthcare policies that are encouraging the growth of the pharmaceutical sector. Moreover, the growing demand for cost-effective generic drugs and significant investment in research and development by pharmaceutical companies are major market trends shaping the market landscape.
Global Pharmaceuticals Market Growth Drivers
Growth in Mergers and Acquisition Activities to Affect the Market Landscape Significantly
In March 2024, Bristol Myers Squibb announced that it completed the acquisition of clinical-stage biopharmaceutical company Karuna Therapeutics, with the aim to strengthen its neuroscience portfolio in a deal worth USD 14 billion. Under this acquisition, Bristol Myers Squibb gained access to the antipsychotic KarXT drug indicated for schizophrenia and other neurological conditions, and Karuna's early-stage and pre-clinical pipeline. Such strategic acquisition and market consolidation activities are anticipated to be a significant market driver in the forecast period, fostering diversification of product portfolios and bolstering the long-term growth of the pharmaceutical sector.
Expansion in Manufacturing Capabilities to Meet Rising Pharmaceuticals Market Demand
In March 2024, it was reported that Swiss multinational manufacturing company Lonza signed an agreement for acquisition of the Genentech manufacturing facility in Vacaville (United States) from pharmaceutical giant F. Hoffmann-La Roche AG in a deal estimated to be USD 1.2 billion. This acquisition aims to amplify Lonza's biologics manufacturing capacity for mammalian therapeutics along with extending the presence of its facility network in the United States. Further, the CDMO intends to invest around CHF 500 million to upgrade the capabilities of the site in order to accommodate the manufacturing needs of mammalian biologics therapies. Such strategic investments in infrastructure expansion by the leading market players are projected to fuel the market growth.
Global Pharmaceuticals Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Favorable Regulatory Environment | One of the major market trends is the increasing improvement in regulatory policies by health regulatory agencies such as FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency). Accelerated approval pathways and priority review programs not only support innovation in the pharmaceutical sector but also ensure expedited entry of crucial drugs to the market. |
| Rising Demand for Biopharmaceuticals | The market is witnessing an increasing focus on biologics such as monoclonal antibodies and recombinant proteins along with the rise of biosimilars as cost-effective alternatives. Moreover, the growing demand for advanced therapies including gene and cell therapies is poised to augment the pharmaceuticals market share. |
| Generic Drugs Market Growth | The increasing demand for affordable and effective healthcare drugs is a major market trend. The growth in generic drugs market is expanding access to essential medicines which also elevates the market value of the pharmaceutical industry. In addition, rising patent expiration for several blockbuster drugs is anticipated to create opportunities for generic drug manufacturers, thereby impacting the market size. |
| Increased Focus on Rare Diseases | Supported by regulatory incentives and growing healthcare awareness among the public, the market is experiencing an increased emphasis on the development of drugs targeting rare diseases. Increased investment in research for rare and genetic disorders further propels the market growth, leading to the introduction of novel therapeutic options. |
Global Pharmaceuticals Market Segmentation
Market Breakup by Molecule Type
- Biologics and Biosimilars (Large Molecules)
- Monoclonal Antibodies
- Vaccines
- Cell and Gene Therapy
- Others
- Conventional Drugs (Small Molecules)
Market Breakup by Product
- Branded
- Generic
Market Breakup by Availability
- OTC
- Prescription
Market Breakup by Therapeutic Area
- Cardiovascular
- Oncology
- Diabetes
- Infectious diseases
- Neurological
- Respiratory
- Immunological
- Genetic and Rare Genetic Diseases
- Others
Market Breakup by Route of Administration
- Oral
- Topical
- Parenteral
- Inhalations
- Others
Market Breakup by Formulation
- Tablets
- Capsules
- Injectable
- Sprays
- Suspensions
- Powders
- Others
Market Breakup by Age Group
- Children
- Adults
- Geriatric
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Pharmaceuticals Market Share
Branded and Generic Pharmaceuticals Poised to Lead the Market Share
Based on the product, the market is segmented into branded and generic pharmaceuticals. The branded pharmaceuticals segment dominates a significant portion of the market share and generates considerable revenue. The segment's growth is ensured by the protection offered by patents for a certain period as well as continuous innovation in drug development. On the other hand, generics are gaining a growing market share in terms of prescription volume, particularly in regions focusing on reducing healthcare costs.
Global Pharmaceuticals Market Analysis by Region
The market is segmented into several key regions covering North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads the market share driven by high healthcare spending, favorable regulatory environment, and significant investment in biotech and pharmaceutical research. The United States and Canada are the key players in the region impacting the market dynamics. For instance, the US government announced the proposal of USD 1.7 trillion for mandatory funding and USD 144.3 billion for discretionary funding to the Department of Health and Human Services (HHS) for the year 2024, which can boost pharmaceutical market size in the country.
The Asia Pacific market is also poised to witness exponential growth in the forecast period, owing to the rapidly growing pharmaceutical markets in countries such as India, China, and Japan. Supportive government initiatives and increasing investment in healthcare infrastructure are some of the factors bolstering the market expansion. For example, in the 2024-25 interim budget, the Indian government offered an increase of 12.5% in funding for the healthcare sector, which is expected to boost the growth of pharmaceuticals in the country.
Leading Players in the Global Pharmaceuticals Market
The key features of the market report include patent analysis, clinical trial analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbott
This American multinational healthcare company develops, manufactures, and markets a broad range of pharmaceutical products and operates in several segments, including nutrition and branded generic pharmaceuticals.
LONZA
This company is considered one of the world's largest healthcare manufacturing organizations and is known for offering diversified products and services to the pharmaceutical and biotechnology markets. Lonza provides contract development and manufacturing services, from early-phase development to commercial manufacturing, and significantly contributes to the pharmaceutical market growth.
F. Hoffmann-La Roche Ltd.
Headquartered in Switzerland, F. Hoffmann-La Roche Ltd. is a prominent player in the market and specializes in the areas of oncology, infectious diseases, immunology, and neuroscience among others. The company is known for bringing highly effective drugs to the market and is considered a global leader in innovative cancer drugs.
Merck KGaA
Operating across healthcare and life sciences domains, this leading science and technology company based in Germany is one of the key players in the pharmaceuticals market. The company has a robust portfolio of well-known pharmaceutical drugs. For instance, it is the developer of the painkiller Vioxx.
Other key players in the market include Johnson & Johnson Services, Inc., Pfizer, Inc., Sanofi S.A., GSK Plc, Bristol-Myers Squibb Co., Novartis AG, AstraZeneca PLC, Eli Lilly & Co., Gilead Sciences, Inc., Amgen Inc., Novo Nordisk AS, and Bayer AG, among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Molecule Type |
|
| Breakup by Product |
|
| Breakup by Availability |
|
| Breakup by Therapeutic Area |
|
| Breakup by Route of Administration |
|
| Breakup by Formulation |
|
| Breakup by Age Group |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Global Pharmaceuticals Market Report
- What was the global pharmaceuticals market value in 2023?
- What is the global pharmaceuticals market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on molecular type?
- What is the market breakup based on product?
- What is the market breakup on the basis of availability?
- What are the various formulations available in the pharmaceuticals market?
- What is the market segmentation based on the therapeutic area?
- What is the market segmentation based on the route of administration?
- What is the market segmentation based on age group?
- What are the major factors aiding the global pharmaceuticals market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to witness expedited growth during the forecast period?
- How do the prevalence and incidence of chronic diseases affect the market landscape?
- What are the major global pharmaceuticals market trends?
- How does the rise in the geriatric population impact the market size?
- Which molecular type of pharmaceuticals will dominate the market share?
- Which product is expected to have a high market value in the coming years?
- Which availability type will experience the highest demand in the market segment?
- Which therapeutic area is projected to contribute to the highest pharmaceuticals market growth?
- Which route of administration will witness a high market value in the forecast period?
- Which formulation is poised to lead the market share?
- Which age group is anticipated to propel the market demand?
- Who are the key players involved in the pharmaceuticals market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Pharmaceuticals Market Overview
3.1 Global Pharmaceuticals Market Historical Value (2017-2023)
3.2 Global Pharmaceuticals Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Pharmaceuticals Market Landscape*
5.1 Global Pharmaceuticals: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Pharmaceuticals: Product Landscape (Top 20 Players)
5.2.1 Analysis by Molecule Type
5.2.2 Analysis by Product Type
5.2.3 Analysis by Availability
5.2.4 Analysis by Therapeutic Areas
5.2.5 Analysis by Route of Administration
5.2.6 Analysis by Formulation
5.2.7 Analysis by Age Group
6 Global Pharmaceuticals Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Pharmaceuticals Market Segmentation (2017-2032)
7.1 Global Pharmaceuticals Market (2017-2032) by Molecule Type
7.1.1 Market Overview
7.1.2 Biologics and Biosimilars (Large Molecules)
7.1.2.1 Monoclonal Antibodies
7.1.2.2 Vaccines
7.1.2.3 Cell and Gene Therapy
7.1.2.4 Others
7.1.3 Conventional Drugs (Small Molecules)
7.2 Global Pharmaceuticals Market (2017-2032) by Product
7.2.1 Market Overview
7.2.2 Branded
7.2.3 Generic
7.3 Global Pharmaceuticals Market (2017-2032) by Availability
7.3.1 Market Overview
7.3.2 OTC
7.3.3 Prescription
7.4 Global Pharmaceuticals Market (2017-2032) by Therapeutic Area
7.4.1 Market Overview
7.4.2 Cardiovascular
7.4.3 Oncology
7.4.4 Diabetes
7.4.5 Infectious diseases
7.4.6 Neurological
7.4.7 Respiratory
7.4.8 Immunological
7.4.9 Genetic and Rare Genetic Diseases
7.4.10 Others
7.5 Global Pharmaceuticals Market (2017-2032) by Route of Administration
7.5.1 Market Overview
7.5.2 Oral
7.5.3 Topical
7.5.4 Parenteral
7.5.5 Inhalations
7.5.6 Others
7.6 Global Pharmaceuticals Market (2017-2032) by Formulation
7.6.1 Market Overview
7.6.2 Tablets
7.6.3 Capsules
7.6.4 Injectable
7.6.5 Sprays
7.6.6 Suspensions
7.6.7 Powders
7.6.8 Others
7.7 Global Pharmaceuticals Market (2017-2032) by Age Group
7.7.1 Market Overview
7.7.2 Children
7.7.3 Adults
7.7.4 Geriatric
7.8 Global Pharmaceuticals Market (2017-2032) by Region
7.8.1 Market Overview
7.8.2 North America
7.8.3 Europe
7.8.4 Asia Pacific
7.8.5 Latin America
7.8.6 Middle East and Africa
8 North America Pharmaceuticals Market (2017-2032)
8.1 North America Pharmaceuticals Market (2017-2032) by Molecule Type
8.1.1 Market Overview
8.1.2 Biologics and Biosimilars (Large Molecules)
8.1.2.1 Monoclonal Antibodies
8.1.2.2 Vaccines
8.1.2.3 Cell and Gene Therapy
8.1.2.4 Others
8.1.3 Conventional Drugs (Small Molecules)
8.2 North America Pharmaceuticals Market (2017-2032) by Product
8.2.1 Market Overview
8.2.2 Branded
8.2.3 Generic
8.3 North America Pharmaceuticals Market (2017-2032) by Availability
8.3.1 Market Overview
8.3.2 OTC
8.3.3 Prescription
8.4 North America Pharmaceuticals Market (2017-2032) by Therapeutic Area
8.4.1 Market Overview
8.4.2 Cardiovascular
8.4.3 Oncology
8.4.4 Diabetes
8.4.5 Infectious diseases
8.4.6 Neurological
8.4.7 Respiratory
8.4.8 Immunological
8.4.9 Genetic and Rare Genetic Diseases
8.4.10 Others
8.5 North America Pharmaceuticals Market (2017-2032) by Route of Administration
8.5.1 Market Overview
8.5.2 Oral
8.5.3 Topical
8.5.4 Parenteral
8.5.5 Inhalations
8.5.6 Others
8.6 North America Pharmaceuticals Market (2017-2032) by Formulation
8.6.1 Market Overview
8.6.2 Tablets
8.6.3 Capsules
8.6.4 Injectable
8.6.5 Sprays
8.6.6 Suspensions
8.6.7 Powders
8.6.8 Others
8.7 North America Pharmaceuticals Market (2017-2032) by Age Group
8.7.1 Market Overview
8.7.2 Children
8.7.3 Adults
8.7.4 Geriatric
8.8 North America Pharmaceuticals Market (2017-2032) by Country
8.8.1 United States of America
8.8.2 Canada
9 Europe Pharmaceuticals Market (2017-2032)
9.1 Europe Pharmaceuticals Market (2017-2032) by Molecule Type
9.1.1 Market Overview
9.1.2 Biologics and Biosimilars (Large Molecules)
9.1.2.1 Monoclonal Antibodies
9.1.2.2 Vaccines
9.1.2.3 Cell and Gene Therapy
9.1.2.4 Others
9.1.3 Conventional Drugs (Small Molecules)
9.2 Europe Pharmaceuticals Market (2017-2032) by Product
9.2.1 Market Overview
9.2.2 Branded
9.2.3 Generic
9.3 Europe Pharmaceuticals Market (2017-2032) by Availability
9.3.1 Market Overview
9.3.2 OTC
9.3.3 Prescription
9.4 Europe Pharmaceuticals Market (2017-2032) by Therapeutic Area
9.4.1 Market Overview
9.4.2 Cardiovascular
9.4.3 Oncology
9.4.4 Diabetes
9.4.5 Infectious diseases
9.4.6 Neurological
9.4.7 Respiratory
9.4.8 Immunological
9.4.9 Genetic and Rare Genetic Diseases
9.4.10 Others
9.5 Europe Pharmaceuticals Market (2017-2032) by Route of Administration
9.5.1 Market Overview
9.5.2 Oral
9.5.3 Topical
9.5.4 Parenteral
9.5.5 Inhalations
9.5.6 Others
9.6 Europe Pharmaceuticals Market (2017-2032) by Formulation
9.6.1 Market Overview
9.6.2 Tablets
9.6.3 Capsules
9.6.4 Injectable
9.6.5 Sprays
9.6.6 Suspensions
9.6.7 Powders
9.6.8 Others
9.7 Europe Pharmaceuticals Market (2017-2032) by Age Group
9.7.1 Market Overview
9.7.2 Children
9.7.3 Adults
9.7.4 Geriatric
9.8 Europe Pharmaceuticals Market (2017-2032) by Country
9.8.1 United Kingdom
9.8.2 Germany
9.8.3 France
9.8.4 Italy
9.8.5 Others
10 Asia Pacific Pharmaceuticals Market (2017-2032)
10.1 Asia Pacific Pharmaceuticals Market (2017-2032) by Molecule Type
10.1.1 Market Overview
10.1.2 Biologics and Biosimilars (Large Molecules)
10.1.2.1 Monoclonal Antibodies
10.1.2.2 Vaccines
10.1.2.3 Cell and Gene Therapy
10.1.2.4 Others
10.1.3 Conventional Drugs (Small Molecules)
10.2 Asia Pacific Pharmaceuticals Market (2017-2032) by Product
10.2.1 Market Overview
10.2.2 Branded
10.2.3 Generic
10.3 Asia Pacific Pharmaceuticals Market (2017-2032) by Availability
10.3.1 Market Overview
10.3.2 OTC
10.3.3 Prescription
10.4 Asia Pacific Pharmaceuticals Market (2017-2032) by Therapeutic Area
10.4.1 Market Overview
10.4.2 Cardiovascular
10.4.3 Oncology
10.4.4 Diabetes
10.4.5 Infectious diseases
10.4.6 Neurological
10.4.7 Respiratory
10.4.8 Immunological
10.4.9 Genetic and Rare Genetic Diseases
10.4.10 Others
10.5 Asia Pacific Pharmaceuticals Market (2017-2032) by Route of Administration
10.5.1 Market Overview
10.5.2 Oral
10.5.3 Topical
10.5.4 Parenteral
10.5.5 Inhalations
10.5.6 Others
10.6 Asia Pacific Pharmaceuticals Market (2017-2032) by Formulation
10.6.1 Market Overview
10.6.2 Tablets
10.6.3 Capsules
10.6.4 Injectable
10.6.5 Sprays
10.6.6 Suspensions
10.6.7 Powders
10.6.8 Others
10.7 Asia Pacific Pharmaceuticals Market (2017-2032) by Age Group
10.7.1 Market Overview
10.7.2 Children
10.7.3 Adults
10.7.4 Geriatric
10.8 Asia Pacific Biotechnology Market (2017-2032) by Country
10.8.1 China
10.8.2 Japan
10.8.3 India
10.8.4 ASEAN
10.8.5 Australia
10.8.6 Others
11 Latin America Pharmaceuticals Market (2017-2032)
11.1 Latin America Pharmaceuticals Market (2017-2032) by Molecule Type
11.1.1 Market Overview
11.1.2 Biologics and Biosimilars (Large Molecules)
11.1.2.1 Monoclonal Antibodies
11.1.2.2 Vaccines
11.1.2.3 Cell and Gene Therapy
11.1.2.4 Others
11.1.3 Conventional Drugs (Small Molecules)
11.2 Latin America Pharmaceuticals Market (2017-2032) by Product
11.2.1 Market Overview
11.2.2 Branded
11.2.3 Generic
11.3 Latin America Pharmaceuticals Market (2017-2032) by Availability
11.3.1 Market Overview
11.3.2 OTC
11.3.3 Prescription
11.4 Latin America Pharmaceuticals Market (2017-2032) by Therapeutic Area
11.4.1 Market Overview
11.4.2 Cardiovascular
11.4.3 Oncology
11.4.4 Diabetes
11.4.5 Infectious diseases
11.4.6 Neurological
11.4.7 Respiratory
11.4.8 Immunological
11.4.9 Genetic and Rare Genetic Diseases
11.4.10 Others
11.5 Latin America Pharmaceuticals Market (2017-2032) by Route of Administration
11.5.1 Market Overview
11.5.2 Oral
11.5.3 Topical
11.5.4 Parenteral
11.5.5 Inhalations
11.5.6 Others
11.6 Latin America Pharmaceuticals Market (2017-2032) by Formulation
11.6.1 Market Overview
11.6.2 Tablets
11.6.3 Capsules
11.6.4 Injectable
11.6.5 Sprays
11.6.6 Suspensions
11.6.7 Powders
11.6.8 Others
11.7 Latin America Pharmaceuticals Market (2017-2032) by Age Group
11.7.1 Market Overview
11.7.2 Children
11.7.3 Adults
11.7.4 Geriatric
11.8 Latin America Biotechnology Market (2017-2032) by Country
11.8.1 Brazil
11.8.2 Argentina
11.8.3 Mexico
11.8.4 Others
12 Middle East and Africa Pharmaceuticals Market (2017-2032)
12.1 Middle East and Africa Pharmaceuticals Market (2017-2032) by Molecule Type
12.1.1 Market Overview
12.1.2 Biologics and Biosimilars (Large Molecules)
12.1.2.1 Monoclonal Antibodies
12.1.2.2 Vaccines
12.1.2.3 Cell and Gene Therapy
12.1.2.4 Others
12.1.3 Conventional Drugs (Small Molecules)
12.2 Middle East and Africa Pharmaceuticals Market (2017-2032) by Product
12.2.1 Market Overview
12.2.2 Branded
12.2.3 Generic
12.3 Middle East and Africa Pharmaceuticals Market (2017-2032) by Availability
12.3.1 Market Overview
12.3.2 OTC
12.3.3 Prescription
12.4 Middle East and Africa Pharmaceuticals Market (2017-2032) by Therapeutic Area
12.4.1 Market Overview
12.4.2 Cardiovascular
12.4.3 Oncology
12.4.4 Diabetes
12.4.5 Infectious diseases
12.4.6 Neurological
12.4.7 Respiratory
12.4.8 Immunological
12.4.9 Genetic and Rare Genetic Diseases
12.4.10 Others
12.5 Middle East and Africa Pharmaceuticals Market (2017-2032) by Route of Administration
12.5.1 Market Overview
12.5.2 Oral
12.5.3 Topical
12.5.4 Parenteral
12.5.5 Inhalations
12.5.6 Others
12.6 Middle East and Africa Pharmaceuticals Market (2017-2032) by Formulation
12.6.1 Market Overview
12.6.2 Tablets
12.6.3 Capsules
12.6.4 Injectable
12.6.5 Sprays
12.6.6 Suspensions
12.6.7 Powders
12.6.8 Others
12.7 Middle East and Africa Pharmaceuticals Market (2017-2032) by Age Group
12.7.1 Market Overview
12.7.2 Children
12.7.3 Adults
12.7.4 Geriatric
12.8 Middle East and Africa Pharmaceuticals Market (2017-2032) by Country
12.8.1 Saudi Arabia
12.8.2 United Arab Emirates
12.8.3 Nigeria
12.8.4 South Africa
12.8.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis (Top 20 Players)
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Clinical Trial Analysis (Top 20 Players)
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Strategic Initiative
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Market Share Analysis, By Region (Top 5 Companies)
17.1.1 Market Share Analysis: Global
17.1.2 Market Share Analysis: North America
17.1.3 Market Share Analysis: Europe
17.1.4 Market Share Analysis: Asia-Pacific
17.1.5 Market Share Analysis: Rest of the World
17.2 Abbott
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 LONZA
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 F. Hoffmann-La Roche Ltd.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Merck KGaA
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Johnson & Johnson Services, Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Pfizer, Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Sanofi S.A.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 GSK Plc
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Bristol-Myers Squibb Co.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Novartis AG
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 AstraZeneca PLC
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Eli Lilly & Co.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Gilead Sciences, Inc.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Amgen Inc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Novo Nordisk AS
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Bayer AG
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
18 Global Pharmaceuticals Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER